Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 2
1989 2
1991 2
1992 2
1993 2
1994 8
1995 5
1996 2
1997 4
1998 3
1999 4
2000 11
2001 5
2002 6
2003 8
2004 5
2005 10
2006 7
2007 14
2008 6
2009 8
2010 9
2011 10
2012 11
2013 8
2014 10
2015 6
2016 5
2017 5
2018 3
2019 3
2020 1
2021 4
Text availability
Article attribute
Article type
Publication date

Search Results

177 results
Results by year
Filters applied: . Clear all
Page 1
Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study.
Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, Lichinitser M, Fujiwara Y, Yardley DA, Viniegra M, Fan M, Jiang Q, Dansey R, Jun S, Braun A. Stopeck AT, et al. Among authors: steger gg. J Clin Oncol. 2010 Dec 10;28(35):5132-9. doi: 10.1200/JCO.2010.29.7101. Epub 2010 Nov 8. J Clin Oncol. 2010. PMID: 21060033 Clinical Trial.
Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Gnant M, Pfeiler G, Steger GG, Egle D, Greil R, Fitzal F, Wette V, Balic M, Haslbauer F, Melbinger-Zeinitzer E, Bjelic-Radisic V, Jakesz R, Marth C, Sevelda P, Mlineritsch B, Exner R, Fesl C, Frantal S, Singer CF; Austrian Breast and Colorectal Cancer Study Group. Gnant M, et al. Among authors: steger gg. Lancet Oncol. 2019 Mar;20(3):339-351. doi: 10.1016/S1470-2045(18)30862-3. Epub 2019 Feb 19. Lancet Oncol. 2019. PMID: 30795951 Clinical Trial.
Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial.
Gnant M, Pfeiler G, Dubsky PC, Hubalek M, Greil R, Jakesz R, Wette V, Balic M, Haslbauer F, Melbinger E, Bjelic-Radisic V, Artner-Matuschek S, Fitzal F, Marth C, Sevelda P, Mlineritsch B, Steger GG, Manfreda D, Exner R, Egle D, Bergh J, Kainberger F, Talbot S, Warner D, Fesl C, Singer CF; Austrian Breast and Colorectal Cancer Study Group. Gnant M, et al. Among authors: steger gg. Lancet. 2015 Aug 1;386(9992):433-43. doi: 10.1016/S0140-6736(15)60995-3. Epub 2015 May 31. Lancet. 2015. PMID: 26040499 Clinical Trial.
Triple-negative breast cancer.
Bartsch R, Ziebermayr R, Zielinski CC, Steger GG. Bartsch R, et al. Among authors: steger gg. Wien Med Wochenschr. 2010 Apr;160(7-8):174-81. doi: 10.1007/s10354-010-0773-6. Wien Med Wochenschr. 2010. PMID: 20473728 Free article. Review.
Resistance to 5-fluorouracil.
Mader RM, Müller M, Steger GG. Mader RM, et al. Among authors: steger gg. Gen Pharmacol. 1998 Nov;31(5):661-6. doi: 10.1016/s0306-3623(98)00191-8. Gen Pharmacol. 1998. PMID: 9809460 Review.
Role of denosumab in breast cancer.
Bartsch R, Steger GG. Bartsch R, et al. Among authors: steger gg. Expert Opin Biol Ther. 2009 Sep;9(9):1225-33. doi: 10.1517/14712590903146877. Expert Opin Biol Ther. 2009. PMID: 19653867 Review.
HER-2-positive breast cancer: hope beyond trastuzumab.
Bartsch R, Wenzel C, Zielinski CC, Steger GG. Bartsch R, et al. Among authors: steger gg. BioDrugs. 2007;21(2):69-77. doi: 10.2165/00063030-200721020-00001. BioDrugs. 2007. PMID: 17402790 Review.
Efficacy and safety of everolimus plus exemestane in patients with HR+, HER2- advanced breast cancer progressing on/after prior endocrine therapy in routine clinical practice: Primary results from the non-interventional study, STEPAUT.
Steger GG, Egle D, Bartsch R, Pfeiler G, Petru E, Greil R, Helfgott R, Marth C, Öhler L, Hubalek M, Lang A, Tinchon C, Haslbauer F, Redl A, Hock K, Hennebelle M, Mraz B, Gnant M. Steger GG, et al. Breast. 2020 Apr;50:64-70. doi: 10.1016/j.breast.2020.01.035. Epub 2020 Jan 31. Breast. 2020. PMID: 32062536 Free PMC article.
177 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page